1245634-25-6

Actoxumab (0.1-10 mg/kg or 50 mg/kg; i.p.; single dose) shows protective effect in multiple murine models of clostridium difficile infection (CDI), including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice^[1].
Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease^[1].